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STAT3 INHIBITOR HAVING ANTI-CANCER 
ACTIVITY AND METHODS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
The present application is a national phase application of 
International Application No. PCT/US2007/086453 filed on 
Dec. 5, 2007, which claims priority to U.S. Provisional Patent 
Application No. 60/868,794 filed on Dec. 6, 2006, each of 
which is incorporated by reference herein it its entirety. 
STATEMENT OF GOVERNMENT INTEREST 
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cessing of Stat3 to understand Stat3's role as a signaling 
intermediate and a molecular mediator of the events leading 
to carcinogenesis and malignant progression. 
The computational analysis of the interaction between the 
5 Stat3 SH2 domain-binding pTyr peptide sequence and the 
SH2 domain, per the X-ray crystal structure of Stat3b bound 
to DNA (14), can generate valuable information about key 
structural requirements for the Stat3:Stat3 dimer formation 
that will facilitate the design of effective small-molecules to 
10 disrupt the dimer. Such molecules can be used for therapeutic 
purposes and as tools for investigating the regulation of Stat3 
protein. In the molecular modeling of the Stat3 pTyr-SH2 
domain interaction, the peptidomimetic inhibitor, ISS 610 
(10) derived from the Stat3 SH2 domain-binding pTyr (Y*) 
This invention was made with support from the U.S. Gov- 15 peptide, PY*LKTK (9), was used as a chemical probe for 
ernment under Grant CA 106439 awarded to James Turkson interrogating the Stat3:Stat3 dimer interface in order to derive 
by the National Cancer Institute. Accordingly, the govern-
ment has certain rights in the invention. 
FIELD OF THE INVENTION 
The present invention relates to the field of cellular biology 
and, more particularly, to a novel inhibitor effective against at 
least one protein of a certain family of proteins of importance 
non-peptide mimics. 
Herein, we describe the design and characterization of a 
novel oxazole-based peptidomimetic, designated S3I-
20 M2001, as a selective disruptor of Stat3:Stat3 dimerization 
and inhibitorofStat3 activation. We also describe our study of 
the stability and intracellular processing of aberrant Stat3 
within the context of the activity of S3I-M2001 as a Stat3 
inhibitor. 
in cancer cell physiology and known as Signal Transducers 25 
and Activators of Transcription (STAT). SUMMARY OF THE INVENTION 
BACKGROUND OF THE INVENTION 
STAT proteins were originally discovered as latent cyto-
plasmic transcription factors that mediate cytokine and 
growth factor responses (1, 2). Seven members of the family, 
Stat!. Stat2. Stat3. Stat4. Stat5a and Stat5b, and Stat6, medi-
ate several physiological effects including growth and differ-
entiation, survival, development and inflammation. STATs 
are SH2 domain-containing proteins. Upon ligand binding to 
cytokine or growth factor receptors. STATs become phospho-
rylated on critical Tyr residue (Tyr705 for Stat3) by growth 
factor receptors, cytoplasmic Janus kinases (Jaks) or Src fam-
ily kinases. Two phosphorylated and activated STAT mono-
mers dimerize through reciprocal pTyr-SH2 domain interac-
tions, translocate to the nucleus, and bind to specific DNA-
response elements of target genes, thereby inducing gene 
transcription (1, 2). In contrast to normal STAT signaling, 
many human solid and hematological tumors harbor aberrant 
Stat3 activity (3-8 for reviews). 
Constitutive Stat3 activity mediates dysregulated growth 
and survival, angiogenesis, as well as suppresses the host's 
immune surveillance of the tumor, making constitutively-
active Stat3 a critical molecular mediator of carcinogenesis 
and tumor progression. 
Genetic and other molecular evidence reveals persistent 
Tyr phosphorylation of Stat3 is mediated by aberrant 
upstream Tyr kinases and shows cancer cell requirement for 
constitutively-active and dimerized Stat3 for tumor mainte-
nance and progression. Thus, in numerous proof-of-concept 
studies (9-13 ), inhibition of Stat3 activation or disruption of 
dimerization induces cancer cell death and tumor regression. 
How aberrant Stat3 is regulated for meeting the tumor-spe-
cific requirements in malignant cells remains undefined. 
There have been no studies into defining the molecular details 
of how malignant cells regulate aberrant Stat3 and how this 
regulation changes upon Stat3 inhibition prior to the onset of 
phenotypic changes, although knowing these events will 
facilitate efforts in modulating aberrant Stat3 for managing 
human cancers. Small-molecule Stat3 inhibitors thus provide 
tools for probing the molecular dynamics of the cellular pro-
Signal Transducer and Activator of Transcription (Stat) 3 is 
hyperactivated in many human tumors and represents a valid 
30 target for small-molecule anticancer drug design. We present 
a novel small-molecule Stat3 dimerization inhibitor, S3I-
M2001 and describe the dynamics of intracellular processing 
of activated Stat3 within the context of the biochemical and 
biological effects of the Stat3 chemical probe inhibitor. S3I-
35 M2001 is a newly-identified oxazole-based peptidomimetic 
of the Stat3 Src Homology (SH) 2 domain-binding phospho-
tyrosine peptide that selectively disrupts active Stat3:Stat3 
dimers. Consequently, hyperactivated Stat3, which hitherto 
occurs as "dot-like" structures of nuclear bodies, undergoes 
40 an early aggregation into non-functional perinuclear aggre-
somes and a late-phase proteasome-mediated degradation in 
malignant cells treated with S3I-M2001. Thus, S3I-M2001 
inhibited Stat3-dependent transcriptional regulation of tumor 
survival genes, such as Bcl-xL. Furthermore. Stat3-depen-
45 dent malignant transformation, survival, and migration and 
invasion of mouse and human cancer cells harboring persis-
tently-activated Stat3 were inhibited by S3I-M2001. The 
ectopic expression of Stat3 SH2 domain rescued cells from 
S3I-M2001-induced apoptotic effects, further confirming a 
50 dimerization inhibition mechanism. Finally, S3I-M2001 
inhibited growth of human breast tumor xenografts. The 
study identifies a novel Stat3 inhibitor, S3I-M2001 and pro-
vides evidence for antitumor cell effects mediated in part 
through a biphasic loss of functional Stat3. The disclosed 
55 study represents the first on intracellular Stat3 stability and 
processing following inhibition by a small-molecule that has 
significant antitumor activity. 
With the foregoing in mind, the present invention advan-
tageously provides a compound designated as S3I-M2001 
60 and having a chemical structure according that shown in FIG. 
lB, or a pharmaceutically acceptable salt thereof. The inven-
tion further includes a pharmaceutically acceptable compo-
sition containing the compound shown in FIG. lB. In one 
preferred embodiment of the invention, a pharmaceutically 
65 acceptable composition contains the compound S3I-M2001 
in an effective amount for inhibiting Stat3 dimerization upon 
contacting a mammalian cell. 
US 8,609,639 B2 
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Method aspects of the invention include treating a mam-
malian cell having a dysfunctional Stat3 protein, the method 
comprising contacting the cell with the compound S3I-
M2001 or with a composition containing the compound. 
Treatment also includes inhibiting a mammalian cell harbor- 5 
ing constitutively active Stat3 by contacting the cell with an 
effective amount of the compound S3I-M2001 or a composi-
tion containing the compound so as to inhibit the Stat3 activ-
ity in the cell. For example, in a method of treating human 
breast or pancreatic cancer characterized by a constitutively 10 
active level of Stat3, the method comprises administering a 
sufficient amount of the compound S3I-M2001, or a compo-
sition containing it, to contact cancer cells in the patient's 
breast or pancreas. 
Alternatively, a patient may be treated to inhibit growth of 15 
a human breast cancer tumor by administering to the patient 
a sufficient amount of the compound of S3I-M2001 or a 
composition containing S3I-M2001. More broadly viewed, 
the invention includes a method of inhibiting migration of a 
malignant cell, the method comprising contacting the cell 20 
with S3I-M2001 as the compound or in a pharmaceutically 
acceptable composition. 
BRIEF DESCRIPTION OF THE DRAWINGS 
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pared from NIH3T3 fibroblasts transiently co-transfected 
with the Stat3-dependent (pLucTKS3) or the Stat3-indepen-
dent (pLucSRE) luciferase reporter together with the v-Src 
plasmid with and without Stat3b plasmid and treated with or 
without S3I-M2001; (B) shows EMSA analysis of STATs 
DNA-binding activities in independently-prepared cell 
lysates of activated Stat! or Stat3, or mixed pool oflysates of 
both proteins and pre-treated with or without S3I-M2001 
concentrations for 30 min at room temperature prior to incu-
bation with radiolabeled hSIE oligonucleotide probe, as 
described in "Methods"; (C) depicts in vitro ELISA for the 
binding ofLck-SH2-GST to the conjugate biotinylated pTyr-
peptide (EPQpYEEIEL) and effects ofS3I-M2001; and (D) 
Immunofluorescence imaging/confocal microscopy of Stat3 
nuclear localization in NIH3T3/hEGFR treated with or with-
out 100 mM S3I-M2001 for 3 h prior to stimulation or 
unstimulation by EGF (rhEGF) for 10 min.: positions of 
STAT:DNA complex in gel are labeled; values are the mean 
and S.D. of 6 replicate experiments; data are representative of 
three independent studies; 
FIG. 4 shows fluorescence with confocal microscopy of 
intracellular Stat3 signal; fluorescence microscopy of the 
NIH3T3/v-Src fibroblasts stably expressing the plasmids for 
(A) and (B) yellow fluorescent protein (YFP)-tagged Stat3 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
25 (NIH3T3/v-Src/Stat3-YFP) or (C) green fluorescent protein 
(GFP) (NIH3T3/v-Src/GFP) and treated with or without S3I-
M2001 for the indicated times in the presence or absence of 
the proteasome inhibitor, MG132 (1-h pre-treatment); and 
Laser scanning confocal microscopy of (D) NIH3T3/v-Src/ 
FIG. 1 shows computational modeling of S3I-M2001 
bound to the Stat3 SH2 domain and S3I-M2001 chemical 
structure according to an embodiment of the present inven-
tion; in panel (A) S3I-M2001 (green) is shown docked to the 
SH2 domain of Stat3, along with Stat3 peptidomimetic 
inhibitor, ISS 610 (yellow) (10); and the chemical structures 
30 GFP (left panel) or NIH3T3/v-Src/Stat3-YFP (right panel) or 
(E) NIH3T3/v-Src/Stat3-YFP and treated with or without 
S3I-M2001 or Cisplatin for the indicated times; fluorescence 
and confocal images were collected using Nikon Eclipse 
TE200 and Leica TCS SP5 microscopes, respectively; 
35 Arrows denote fluorescence or cells previously showing fluo-
rescence, or aggregated Stat3-YFP; data are representative of 
2-3 independent studies: 
of S3I-M2001 (panel B) or ISS 610 (panel C) are shown; FIG. 5 displays immunoblotting analyses of intracellular 
Stat3 signal; SDS-PAGE/Westem blot analysis of(A) whole-
40 cell lysates from NIH3T3/v-Src/Stat3-YFP probing forYFP, 
Stat3 or b-actin; and (B) of Stat3 immunoprecipitates from 
NIH3T3/v-Src fibroblasts blotting for Ubiquitin, or NIH3T3/ 
v-Src whole-cell lysates blotting for Stat3 or b-actin; data are 
FIG. 2 depicts the effects ofS3I-M2001 on STATs activa-
tion, and on pJakl, pSrc, pErkl/2; (A) shows EMSA analysis 
ofSTATs DNA-binding activities in nuclear extracts contain-
ing activated Stat3 (left panel) or Stat! and Stat3 (middle 
panel) and pre-treated with S3I-M2001 concentrations for 30 
min. at room temperature prior to incubation with radiola-
beled hSIE oligonucleotide probe, and IC50 values for the 45 
inhibition of STATs DNA-binding activity in vitro (right 
panel) derived, as described in "Methods"; (B) EMSA analy-
representative of 2-3 independent studies; 
FIG. 6 shows immunofluorescence with laser scanning 
confocal imagining of Stat3 aggregation into perinuclear 
aggresomes induced by S3I-M2001: immunofluorescence 
and confocal microscopy ofNIH3T3/v-Src fibroblasts grow-
ing in culture treated with or without S3I-M2001 or Cisplatin 
50 for the indicated times, (A) fixed and stained with rabbit 
anti-Stat3 antibody (green) or DAPI nuclear staining (blue); 
(B) allowed to recover from the effects ofS3I-M2001 for 2 h 
or 19 h prior to fixing and staining for Stat3 or with DAPI; or 
(C) fixed and stained with rabbit antibody against Stat3 
sis of Stat3 DNA-binding activity in nuclear extracts from 
NIH3T3/v-Src or MDA-MB-231 cells, or from recombinant 
human EGF (rhEGF)-stimulated NIH3T3/hEGFR mouse 
fibroblasts treated with or without S3I-M2001; and (C) SDS-
PAGE/Westem blot analysis of whole-cell lysates prepared 
from S3I-M2001-treated or untreated NIH3T3/v-Src or 
MDA-MB-435 cells probing for pTyr705Stat3, Stat3, pJak, 
Jakl, pSrc, Src, pErkl/2, Erkl/2, and b-actin; positions of 
STAT:DNA complex in gel, pTyrStat3 and Stat3 are labeled; 
values are the mean and S.D. of3 replicate experiments: data 
are representative of three independent studies; IC50 values 
were determined by quantifying by ImageQuant the bands 
corresponding to the STAT:DNA complexes; control lanes 60 
represent nuclear extracts untreated with S3I-M2001 or 
nuclear extract preparations from cells untreated with the 
compound; 
FIG. 3 illustrates the effects of S3I-M2001 on Stat3 tran-
55 (green) or goat antibody against Hook2 (blue); arrows denote 
aggregated Stat3 and localization of Hook2 protein; images 
were captured using Leica TCS SP5 laser scanning confocal 
microscope and are representative of 3 independent experi-
ments; 
scriptional activity and dimerization, and nuclear localiza- 65 
tion, and on the Lck-SH2 domain function; in (A) are shown 
luciferase reporter measurements in cytosolic extracts pre-
FIG. 7 shows effect ofS3I-M2001 on cell viability, malig-
nant transformation, apoptosis and Bcl-xL expression: in (A) 
IC50 values for the S3I-M2001-induced loss of cell viability 
determined by WST-1 assay; (B) anchorage-independent 
growth in soft-agar suspension of malignant cells (NIH3T3/ 
v-Src. Pane-I and NIH3T3/v-Ras) treated with or without 
S3I-M2001 every three days; (C) TUNEL staining for DNA 
damage in normal NIH3 T3 and NIH3 T3/v-Src, human endot-
US 8,609,639 B2 
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helial (HUVEC), breast cancer cells (MDA-MB-453, MDA-
MB-231 and MDA-MB-435), and the normal breast epithe-
lial MCF-lOA cells treated with or without S3I-M2001 for48 
h; Stat3 activity status is indicated as ( + ), pStat3 (activated), 
(-), no Stat3 activity; (D) Annexin V binding and Flow 5 
Cytometry of NIH3T3/v-Src fibroblasts transfected with 
empty vector, pcDNA3 (3T3/v-Src/pcDNA3) or the Stat3 
SH2 domain (3T3/v-Src/ST3-SH2) for 4 h or untransfected 
(3T3/v-Src) and treated with or without 100 mM S3I-M2001 
for additional 24 h; and (E) SDS-PAGE and Western blot 
10 
analysis for Bcl-xL in NIH3T3/v-Src and MDA-MB-435 
cells; images shown are representative of 2-3 independent 
studies; values are the mean and S.D. of3-4 replicate experi-
ments; 
FIG. 8 shows that S3I-M2001 suppresses malignant cell 
migration and invasion and inhibits growth of human breast 15 
tumor xenografts; in (A) viral Src-transformed mouse fibro-
blasts (NIH3T3/v-Src), human breast cancer (MDA-MB-
231) and pancreatic cancer (Pane- I) cells were seeded for 
studies in migration on filters or invasion on matrigel-coated 
filters in Bio-Coat chambers and treated with or without S3I- 20 
M2001 (100 mM) for 24; cells on other side of filters were 
photographed (upper panel) and quantified under light micro-
scope (lower panel; percent inhibition in parenthesis): human 
breast (MDA-MB-231) tumor-bearing mice were given S3I-
M2001 (5, 10 and 20 mg kg-1) i.v. every 2 or 3 days; (B) 25 
Tumor sizes, measured every 2 or 3 days, were converted to 
tumor volumes and plotted against treatment days; (C) EMSA 
analysis ofStat3 DNA-binding activity in lysates from tumor 
tissues extracted from one control and two residual treated 
tumors (Tl and T2) 3 days after the last S3I-M2001 (5 mg 30 
kg-1) injection; and (D) SDS-PAGE/Western blot analysis of 
whole-cell lysates from control or residual treated (T2) tumor 
tissue and probing for pTyr705Stat3 and Stat3; values are the 
mean and S.D. of three independent experiments each in 
duplicates or replicates of 12 tumor-bearing mice in each 35 
group; data are representative of 2-3 independent experi-
ments; bands ofStat3:DNA complexes, pStat3 and Stat3 are 
shown: 
FIG. 9 shows effects ofS3I-M2001 on STATs activation by 
EMSA analysis of Stat3 DNA-binding activity in cell lysate 40 
containing activated Stat3 prepared from Sf-9 cells infected 
with Stat3. Jakl, and c-Src baculoviruses: positions of STAT: 
DNA complex in gel are labeled; data shown are representa-
tive of 3 independent experiments: 
FIG. 10 depicts the effects of S3I-M2001 on Stat3 phos- 45 
phorylation by immunohistochemical stmmng for 
pTyr705Stat3 in NIH3T3/v-Src or MDA-MB-435 cells; 
images are representative of three independent studies; 
6 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the 
present specification, including any definitions, will control. 
In addition, the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may, however, be embodied in 
many different forms and should not be construed as limited 
to the illustrated embodiments set forth herein. Rather, these 
illustrated embodiments are provided so that this disclosure 
will be thorough and complete, and will fully convey the 
scope of the invention to those skilled in the art. Other fea-
tures and advantages of the invention will be apparent from 
the following detailed description, and from the claims. 
Abbreviations used herein are as generally accepted and 
used by those skilled in the art and include the following: 
STAT, signal transducer and activator of transcription; PBS, 
phosphate-buffered saline; EMSA, electrophoretic mobility 
shift assay; FBS, fetal bovine serum; PMSF, phenylmethyl-
sulfonylfluoride; and PNPP, p-nitrophenyl phosphate; YFP, 
yellow fluorescent protein; GFP, green fluorescent protein; 
CVFF, consistent valence forcefield; and CCDC, Cambridge 
Crystallographic Data Center. 
Those skilled in the art will recognize that this invention 
encompasses pharmaceutical compositions and dosage forms 
containing the disclosed compound of the invention as an 
active ingredient. A "pharmaceutically acceptable composi-
tion" is compatible with the subject's physiology and may 
contain one or more pharmaceutically acceptable carriers or 
excipients. Some of these pharmaceutical compositions may 
be single unit dosage forms suitable for oral, topical, mucosa! 
(e.g., nasal, pulmonary, sub lingual, vaginal, buccal, or rectal), 
parenteral (e.g., subcutaneous, intravenous, bolus injection, 
intramuscular, or intraarterial ), or trans dermal administration 
to a patient. As known to the skilled, examples of dosage 
forms include, without limitation: tablets; caplets; capsules, 
such as soft elastic gelatin capsules; cachets; troches; loz-
enges; dispersions; suppositories; ointments; poultices; 
pastes; powders; dressings; creams; plasters; solutions; 
patches; aerosols such as nasal sprays or inhalers; gels; liquid 
dosage forms for oral or mucosa! administration, including 
aqueous or non-aqueous liquid suspensions, oil-in-water 
emulsions, or water-in-oil liquid emulsions, solutions, and 
elixirs; liquid dosage forms suitable for parenteral adminis-
tration to a patient; and sterile solids such as crystalline or 
amorphous solids that can be reconstituted to provide liquid 
dosage forms suitable for parenteral administration to a 
FIG. 11 illustrates the effect of S3I-M2001 on malignant 
transformation; images of cellular morphology are visualized 50 
using light microscope of normal NIH3T3 mouse fibroblasts 
and v-Src-transformed counterparts (NIH3T3/v-Src) grow-
ing in culture and treated with or without different concen-
trations ofS3I-M2001for48 h; the images shown are repre-
sentative of 2 independent studies; and 55 patient. 
FIG. 12 shows the effect of S3I-M2001 on Bcl-xL expres-
sion by immunohistochemical staining for Bcl-xL in 
NIH3T3/v-Src and human breast cancer MDA-MB-435 
The skilled will also know that a formulation should suit 
cells; intense red staining indicates presence ofBcl-xL, while 
blue staining indicates absence ofBcl-xL; the images shown 60 
are representative of3 independent studies. 
the mode of administration. For example, oral administration 
may require an enteric coating to help protect the active 
ingredient from degradation in the gastrointestinal tract. The 
S3I-M2001 may also be administered in a liposomal formu-
lation to shield it from enzymes that may degrade it, to facili-
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
tate transport in the blood and to aid in its delivery across cell 
membranes. 
The composition of S3I-M2001, shape, and type of dosage 
65 forms of the invention will typically vary depending on the 
intended use. Thus, it would follow that in the acute treatment 
of a disease the dosage may contain larger amounts of the 
US 8,609,639 B2 
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cells can be characterized as having abnormally elevated 
levels of tyrosine phosphorylated Stat3. 
As used herein, the terms "treat," "treating" or "treatment" 
refer to both therapeutic treatment and prophylactic or pre-
ventative measures, wherein the object is to prevent or slow 
down (lessen) an undesired physiological change or disorder, 
such as the development or spread of cancer or other prolif-
eration disorder. For purposes of this invention, beneficial or 
desired clinical results include, but are not limited to, allevia-
compound, whereas in the chronic treatment of the same 
disease a lower dosage may suffice. Likewise, smaller 
amounts ofS3I-M2001 may be used in a parenteral dose than 
in an dose form used to treat the same disease. The ways in 
which specific dosage forms for the invention may be 
changed will be appreciated by the skilled, particularly with 
reference to a recognized treatise such as Remington's Phar-
maceutical Sciences, 18th ed., Mack Publishing, Easton Pa. 
(1990). 
As used herein, the term "Stat" refers to signal transducers 
and activators of transcription, which represent a family of 
proteins that, when activated by protein tyrosine kinases in 
the cytoplasm of the cell, migrate to the nucleus and activate 
gene transcription. Examples of mammalian STATs include 
STAT 1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and 
STATE. 
10 tion of symptoms, diminishment of extent of disease, stabi-
lized (i.e., not worsening) state of disease, delay or slowing of 
disease progression, amelioration or palliation of the disease 
state, and remission (whether partial or total), whether detect-
able or undetectable. For example, treatment with a com-
15 pound of the invention may include reduction of undesirable 
cell proliferation, and/or induction of apoptosis and cytotox-
icity. "Treatment" can also mean prolonging survival as com-
pared to expected survival if not receiving treatment. Those in 
need of treatment include those already with the condition or 
The term "pharmaceutically acceptable salt or prodrug" is 
intended to describe any form (such as an ester, phosphate 
ester, salt of an ester or a related group) of a compound of the 
invention, which, upon administration to a subject, provides 
the mature or base compound (e.g., the Stat3-inhibitory com-
pound S3I-M2001). Pharmaceutically compatible salts 
include those derived from inorganic or organic bases and 
acids which are compatible with the subject's physiology. 
Suitable salts include those derived from alkali metals such as 
potassium and sodium, alkaline earth metals such as calcium 
and magnesium, among numerous other acids well known in 
the pharmaceutical art. Pharmaceutically acceptable pro-
drugs refer to a compound that is metabolized, for example 30 
hydrolyzed or oxidized, in the host to form the compound of 
the present invention. Typical examples of prodrugs include 
compounds that have biologically labile protecting groups on 
20 disorder as well as those prone to have the condition or 
disorder or those in which the condition or disorder is to be 
prevented or onset delayed. Optionally, the patient may be 
identified (e.g., diagnosed) as one suffering from the disease 
or condition (e.g. proliferation disorder) prior to administra-
25 tion of the Stat3 inhibitor of the invention. 
a functional moiety of the active compound. Prodrugs include 
compounds that can be oxidized, reduced, aminated, deami- 35 
nated, hydroxylated, dehydroxylated, hydrolyzed, dehydro-
lyzed, alkylated, dealkylated, acylated, deacylated, phospho-
rylated, dephosphorylated to produce the active compound. 
The terms "signaling" and "signaling transduction" repre-
sent the biochemical process involving transmission of extra- 40 
cellular stimuli, via cell surface receptors through a specific 
and sequential series of molecules, to genes in the nucleus 
resulting in specific cellular responses to the stimuli. 
"Constitutive activation" and "constitutively active," as in 
the constitutive activation of the STAT pathway, refers to a 45 
condition where there is an abnormally elevated level of 
tyrosine phosphorylated STAT3 within a given cell(s). e.g., 
cancer cells, as compared to a corresponding normal (e.g., 
non-cancer or non-transformed) cell. Constitutive activation 
of STAT3 has been exhibited in a large variety of malignan- 50 
cies, including, for example, breast carcinoma cell lines; pri-
mary breast tumor specimens; ovarian cancer cell lines and 
tumors: multiple myeloma tumor specimens; and blood 
malignancies, such as acute myelogenous leukemia, as 
described in published PCT international application WO 55 
00/44774 (Jove. R. et al.), the disclosure of which is incorpo-
rated herein by reference in its entirety. 
As used herein, the term "(therapeutically) effective 
amount" refers to an amount of the compound of the invention 
or a composition containing the compound effective to treat a 
disease or disorder in a mammal or a mammalian cell. In the 
case of cancer or other proliferation disorder, the therapeuti-
cally effective amount of the agent may reduce (i.e., slow to 
some extent and preferably stop) unwanted cellular prolifera-
tion; reduce the number of cancer cells; reduce the tumor size; 
inhibit (i.e., slow to some extent and preferably stop) cancer 
cell infiltration into peripheral organs; inhibit (i.e., slow to 
some extent and preferably stop) tumor metastasis; inhibit, to 
some extent, tumor growth; reduce Stat3 signaling in the 
target cells (such as by inhibiting the binding of DNA and 
Stat3), and/or relieve, to some extent, one or more of the 
symptoms associated with the cancer. To the extent the 
administered compound or composition prevents growth and/ 
or kills existing cancer cells, it may be cytostatic and/or 
cytotoxic. For cancer therapy, efficacy can, for example, be 
measured by assessing the time to disease progression (TTP) 
and/or determining the response rate (RR). 
The terms "inhibit" or "inhibitory amount" when referring 
to the compound of the invention indicate an amount which 
slows or stops growth or proliferation of a target cell, such as 
a tumor cell, either in vitro or in vivo, irrespective of the 
mechanism by which cell growth is inhibited (e.g., by cyto-
static properties, cytotoxic properties, etc.). 
The terms "cell" and "cells" are used interchangeably 
herein and are intended to include either a single cell or a 
plurality of cells, in vitro or in vivo, unless otherwise speci-
fied. 
FIGS. 1-8 visually present various aspects of the presently 
described invention and are more fully discussed below with 
reference to the results and conclusions derived from the 
investigation leading to the invention. 
60 Methods 
Methods for determining whether a human or non-human 
mammalian cell or subject has abnormally high levels of 
constitutively-activated Stat3 are known in the art and are 
described, for example, in U.S. patent publication 2004-
0138189-Al and PCT publication 02/078617 A, each of 
which are incorporated herein by reference in its entirety. 
Optionally, the methods of the invention further comprise 
identifying a patient suffering from a condition (e.g., cancer) 65 
associated with an abnormally elevated level of tyrosine 
phosphorylated STAT3, or determining whether the cancer 
Cells and Reagents. 
Normal mouse fibroblasts (NIH3T3) and counterparts 
transformed by v-Src transformed (NIH3T3/v-Src), v-Ras 
(NIH3T3/v-Ras), or overexpressing the human EGFR 
(NIH3T3/hEGFR), human breast cancer (MDA-MB-435, 
MDA-MB-453, MDA-MB-231 andMDA-MB-468), immor-
talized human breast epithelial cells. MCF-1 OA, and pancre-
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atic cancer (Pane- I) cell lines have all been previously 
described (9-I2, I7, IS, 40). Human umbilical vein cells 
(HUVEC) was a kind gift Dr. S. Chellappan of Moffitt Cancer 
Center and Research Institute (Tampa, Fla.). Cells were 
grown in Dulbecco's modified Eagle's medium (DMEM) 5 
containing 5% iron-supplemented bovine calf serum: MCF-
IOA were grown in DMEM:FI2 media supplemented with 
5% FBS, I 0 mg mL- I insulin, 500 ng mL- I hydrocortisone, 
20 ng mL-I EGF, and IOO ng mL-I cholera toxin. HUVEC 
cells were grown in Ham's FI2k medium with 2 mM 10 
L-glutamine containing 1.5 g L-I sodium bicarbonate and 
supplemented with O.I mg mL-I heparin and 0.03 mg mL-I 
endothelial cell growth supplement, and IO% FBS. WST-I 
viability assay reagent was obtained from Roche and TUNEL 
assay kit was from BD Biosciences Pharmingen. Each treat- 15 
ment condition is a single dose at the indicated concentration 
10 
ible element from the c-fos gene, m67 variant, as reported by 
Wagner et al. ( 42), and that binds Statl and Stat3. Except 
where indicated, inhibitor compound was pre-incubated with 
the nuclear extract for 30 min at room temperature prior to 
incubation with radiolabeled hSIE probe. Where necessary, 
cells were stimulated with recombinant human EGF (rhEGF) 
for 5-I 5 min prior to preparation of nuclear extracts. Bands 
corresponding to DNA-binding activities were scamied and 
quantified for each concentration of compound and plotted as 
percent of control (vehicle) against concentration of com-
pound, from which the IC50 values were derived, as previ-
ously reported (9, IO, 42). 
Immunoprecipitation (i.p.) and SDS-PAGE/Western Blot 
Analysis. 
Whole-cell lysates prepared in boiling SDS sample-load-
ing buffer. i.p. from lysates using monoclonal anti-Stat3 anti-
body (Cell Signaling Technology), and the probing of nitro-
cellulose membranes with primary antibodies and detection 
or O.I% DMSO (vehicle) as control. Anti-Hook2 antibody 
was from Santa Cruz. Plasmids. The pLucTKS3 and pLuc-
SRE luciferase reporters have been previously reported (I 7, 
I9). 
Computational Modeling of the Stat3 SH2 Domain-ISS 6IO 
Complex. 
As a first step towards designing new Stat3 inhibitors as 
probes or novel anticancer therapeutics, molecular modeling 
20 of horseradish peroxidase-conjugated secondary antibodies 
by enhanced chemiluminescence (Amersham Biosciences) 
were done, as previously described (I3, I7, I9, 2I). The 
probes used were anti-Stat3 (Santa Cruz), anti-pTyr705Stat3 
(Cell Signaling Technology), anti-YFP antibodies (Santa 
Cruz), anti-Bcl-xL, anti-pSrc, anti-Src, anti-pJakI, anti-JakI, 
anti-pErI/2 and anti-ErkI/2, and b-actin (Cell Signaling 
Technology). 
Dissociation-Reassociation Analysis. 
The dissociation-reassociation analysis with EMSA analy-
sis was performed, as previously done (IO, 20). 
Immunohistochemistry. 
The indirect peroxidase-anti peroxidase test was performed 
on cytospins prepared from cell lines (control and treated with 
50 mM S3I-M200I for 48 h). Immunostaining was performed 
for p Y705Stat3 with a rabbit anti-human polyclonal p YStat3 
antibody (Cell Signaling Technology) and for Bcl-xL with 
rabbit monoclonal (EIS) antibody (Abeam, Inc., Cambridge, 
Mass.) with rabbit immunoglobulins as negative controls 
using avidin-biotin-peroxidase complexes (Vector Laborato-
of the Stat3 SH2 domain was performed. The Stat3 SH2 25 
domain contains trigonal arrangement of shallow pockets, 
deemed accessible by suitably-substituted heterocyclic scaf-
folds, such as the oxazole, S3I-M2001. Docking of S3I-
M2001 into Stat3 was performed using the GOLD software 
(I5) by CCDC. Compounds were drawn with Insight II (Ac- 30 
celrys), and energy minimized to a local minimum using the 
CVFF forcefield. The Stat3 protein was prepared for use in 
GOLD by adding Hydrogen atoms to the X-ray crystal struc-
ture, lBGl.pdb (I4. Compounds were docked by GOLD IO 
times each using default settings within GOLD and were 35 
scored using the default GO LDScore scoring function. Maxi-
mum ligand flexibility was allowed during docking cycles by 
allowing ring flipping, amide cis/trans alteration, and amine 
flipping. After I 0 <lockings, the conformation with the highest 
score for each compound was considered and analyzed. 
Compound Synthesis. 
The design strategy for the construction of the oxazole 
scaffold was carried out using standard synthetic procedures, 
following the principle of rapid incorporation of structural 
diversity into an acyclic precursor, with subsequent late stage 45 
aromatization providing the desired heteroaryl array ( 4 I). 
Recombinant Baculoviruses, Infection of Sf-9 Insect Cells 
and Cytosolic Lysates Preparation. 
40 ries, Burlingame, Calif.). After incubation and blocking of 
endogenous peroxidase and nonspecific background staining 
in 3% hydrogen peroxide and methanol for 20 min, slides 
were washed with PBS, treated with I .5% normal serum and 
Infect of Sf-9 cells with Statl, Stat3, JakI, and c-Src 
recombinant baculoviruses and preparation of the cell lysates 50 
containing activated Statl or Stat3 have been previously 
described (9, 2I). 
Stat3 Inhibitory Property of S3I-M200I; Nuclear Extract 
Preparation and Gel Shift Assays. 
In the previously reported dissociation-reassociation 55 
analysis (9, IO, 20), two independently-prepared cell lysate, 
one containing only activated Stat3:Stat3 dimer and the other 
containing only activated Statl :Statl dimer (2I ), were mixed 
together and pre-treated with or without increasing concen-
tration of S3I-M200I and subjected to STAT DNA-binding 60 
assay with EMSA analysis. 
Nuclear extract preparation from cells and EMSA were 
carried out as previously described (9-I2, I 6, I 8, 40). Nuclear 
extract preparations from v-Src-transformed (NIH3T3/v-
Src) or EGF-stimulated NIH3T3/hEGFR fibroblasts, or 65 
tumor cell lines were subjected to EMSA. The 32P-labeled 
oligonucleotide probe used was hSIE (high affinity sis-induc-
3% BSA, and incubated with the pY705Stat3 or Bcl-xL pri-
mary antibodies overnight at 4 ° C. Slides were rinsed in PBS 
and incubated with a biotinylated secondary antibody (Vector 
Laboratories) for 60 min, followed by incubation with avidin-
biotin-peroxidase complex for I hat room temperature. Chro-
ma gen was developed with Nova-Red. All slides were coun-
terstained with hematoxylin for 30 s before dehydration and 
mounting. Phospho Y705Stat3 or Bcl-xL positive cells were 
stained red (due to Nova-Red) and negative cells were stained 
blue (due to hematoxylin). 
Lck-SH2 Domain ELISA Assay. 
An ELISA assay for the binding ofLck-SH2 domain with 
its conjugate phosphopeptide, biotinyl-e-Ac-EPQpYEEIEL-
OH, was carried out, as previously described (13, 22). Absor-
bancereading ( 450 nm) for the peroxidase reaction was deter-
mined with an ELISA plate reader. 
Fluorescence Microscopy. 
NIH3T3/vSrc cells were either stably transfected with 
Stat3-YFP construct (23), or growing in 96-well plates on 
chamber slides were transiently transfected with the Stat3-
YFP plasmid (23) using Lipofectamine 2000 for 24 h accord-
ing to the manufacturer's protocol (Roche), treated with or 
without S3I-M2001 for different times, and examined under 
Nikon Eclipse TE200 fluorescence microscope (Nikon). 
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Images were captured and processed by NIKON NIS ele-
ment-Basic research software. 
Confocal Microscopy. 
12 
NIH3T3/hEGFR cells were grown in multi-cell plates and 
treated with or without S3I-M2001 for3 h prior to stimulation 5 
by rhEGF (10 ng/ml) for 10 min or NIH3 T3/vSrc cells were 
grown in multi-cell plates or chamber slides and cells were 
fixed with 4% paraformaldehyde for 15 min. Cells were 
washed 3 times in PBS, permeabilized with 0.2% Triton X for 
invasion experiments were performed using same Bio-Coat 
invasion chambers (Becton Dickenson), as already described, 
except that here, filters (8 mm) were used coated with the 
basement membrane matrigel. Percent inhibition is calcu-
lated as 100-y, where y equals residual number of stained 
cells in the treated/total number in the control xlOO. 
Mice and In Vivo Tumor Studies. 
Six-week-old female athymic nude mice were purchased 
from Harlan and maintained in the institutional animal facili-
ties approved by the American Association for Accreditation 
of Laboratory Animal Care. Athymic nude mice were injected 
subcutaneously in the left flank area with 5x106 human breast 
cancer MDA-MB-231 cells in 100 mL of PBS. After 5 to 10 
days, tumors of a diameter of3 mm were established. Animals 
5 min, and further washed 3-4 times with PBS. Specimens 10 
were then blocked in 5% goat serum for 60 min and incubated 
with Stat3 (Cell Signaling Technology) or Hook2 (Santa 
Cruz, Santa Cruz, Calif.) antibody at 1:50 dilution at 4° C. 
overnight. Subsequently, cells were rinsed 4-5 times in PBS, 
incubated with Alexa fluor 488 rabbit antibody (Molecular 15 
probe, Eugene, Oreg.) for (Stat3 detection) or NL637 goat 
antibody (R&D Systems, Minneapolis, Minn.) for Hook2 for 
1-2 hat room temperature in the dark. Specimens were then 
washed 5 times with PBS, covered with cover slides with 
VECTASHIELD mounting medium containing DAPI, and 20 
examined immediately under Lei ca TCS SP5 confocal micro-
scope (Germany) at appropriate wavelengths depending on 
GFP or YFP. Images were captured and processed using the 
Leica TCS SP 5 software. 
were grouped so that the mean tumor sizes in all groups were 
nearly identical, given S3I-M2001 i.v. at 5, 10 and 20 mg/kg 
every 2 or every 3 days for 26 days and monitored every 2 or 
3 days, and tumor sizes were measured with calipers. Tumor 
volume was calculated according to the formula V=0.52xa2x 
b, where a, smallest superficial diameter, b, largest superficial 
diameter. 
Results and Discussion 
Computational Modeling of the Stat3 SH2 Domain-ISS 610 
Complex. 
Soft-Agar Colony Formation Assay. 
Colony formation assays were carried out in six-well 
dishes and colonies were enumerated as previously described 
(19). Treatment with S3I-M2001 was initiated 1 day after 
seeding cells in soft-agar suspension by adding 75-100 mL of 
medium with or without compound, and repeated every three 
days, until large colonies were evident. 
Cell Viability Assay, TUNELAnalysis, andAnnexin V Bind-
ing and Flow Cytometry. 
Normal NIH3T3 and NIH3T3/v-Src mouse fibroblasts 
growing in culture were treated with or without 10-100 mM 
S3I-M2001 for 48 h. Cells were then visualized under light 
microscope and photographed with a digital camera. 
Proliferating cells in 96-well plates were treated with 
50-300 mM S3I-M2001for48 h for WST-1 assay, according 
to manufacturer's (Roche) instructions, or cells growing in 
culture and treated with or without S3I-M2001 for 48 h were 
harvested for analysis by terminal nucleotidyl transferase 
mediated dUTP nick end labeling (TUNEL) staining accord-
ing to supplier's (Roche) instructions to detect apoptotic 
cells. In some cases, cells were first transfected with the 
plasmid forthe Stat3 SH2 (ST3-SH2) domain or mock-trans-
fected (pcDNA3 empty vector) for 24 h or untransfected prior 
to treatment with S3I-M2001 for an additional 24-48 h. Cells 
were then detached and analyzed by Annexin V binding (BD 
Biosciences, San Diego) according to the manufacturer's pro-
tocol and Flow Cytometry to quantify the percent apoptosis. 
Cell Migration and Matrigel Invasion Assays. 
Cell migration experiments were carried out using Bio-
Coat migration chambers (Becton Dickinson, Franklin, N.J.) 
of24-well companion plates with cell culture inserts contain-
ing 8 mm pore size filters, according to the manufacturer's 
protocol. Briefly, tumor cells (5x104/500 ml) were added to 
each insert (upper chamber) with or without S3I-M2001 and 
medium with serum (10% FBS) as the chemoattractant was 
placed in each well of a 24-well companion plate (lower 
chamber). After 24-h incubation (37° C., 5% C02), the filters 
were removed and the upper surface was wiped with a cotton-
tipped applicator to remove non-migratory cells. Cells that 
had migrated through the filter pores and attached to bottom 
surface of the filter were fixed and stained. The membranes 
were mounted on glass slides and cells from 10 random 
microscopic fields (x400 magnification) were counted. Cell 
25 Close structural analysis of the lowest genetic optimization 
for ligand docking (GOLD) (15) conformation of ISS 610 
(yellow) (IC50=42 µM for inhibition of Stat3:Stat3 (10)) 
bound within the Stat3 SH2 domain (FIG. IA), per the X-ray 
crystal structure of Stat3b (14), indicated key structural 
30 requirements for hydrophobic, hydrogen-bonding, and elec-
trostatic interactions critical for tight binding. Appropriate 
candidate binders are suitably-substituted heterocyclic sys-
tems that reproduce the critical ISS 610-Stat3 interactions. 
Hence, S3I-M2001 (FIG. IB), which contained a central 
35 oxazole core with two hydrophobic substituents to comple-
ment the relatively hydrophobic protein surface and a pTyr 
group to bind to the phosphate recognition residues of the 
third pocket, and which superimposes well with the parent 
ISS 610 docked into the same SH2 cavity (FIG. IA). Docking 
40 studies of S3I-M2001 identified significant complementary 
interactions between the protein surface and the molecule. 
The pTyr moiety is bound tightly within a hydrophilic cleft 
composed of Arg609, Ser613 and Ser611. This important 
contact may predetermine the subsequent orientations of the 
45 two lipophilic groups within the hydrophobic regions of the 
SH2 domain. The naphthy 1 appendage makes significant con-
tact with the Ile634 side chain and the lipophilic hexyl sub-
stituent is partially encased within a hydrophobic channel 
composed primarily of Phe716 and Trp623. Positive cooper-
50 ativity may exist between these subunits to provide a highly 
potent binding agent for the SH2 active site. 
Stat3-Inhibitory Property of S3I-M2001. 
Per DNA-binding assay/EMSA analysis (see "Methods" 
for details). S3I-M2001 favorably disrupts Stat3 activity in 
55 vitro in nuclear extracts containing activated Stat3 (FIG. 2A, 
left panel) or in lysates from Sf-9 cells containing activated 
Stat3, and preferentially inhibits Stat3 activity over Stat! by 
2-fold (IC50 values (mM), Stat3:Stat3, 79±09; Statl:Stat3, 
92±11; and Statl:Statl, 159±06 (FIG. 2A, middle and right 
60 panels). Similarly, per DNA-binding assay/EMSA analysis 
(FIG. 2B). SDS-PAGE/Westem blot (FIG. 2C) and immuno-
cytostaining analyses, S3I-M2001 inhibited constitutive 
Stat3 Tyr phosphorylation and activation in the NIH3T3/v-
Src and the human breast cancer MDA-MB-231 and MDA-
65 MB-435 cell lines that harbor constitutively-active Stat3 (16-
18) (FIG. 2B, lanes 1-13, and 2C, lanes 1-6), and 
preferentially inhibited the epidermal growth factor (rhEGF)-
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induced Stat3 activation over that of Statl in the mouse fibro-
blasts overexpressing the human EGF receptor (NIH3T3/ 
hEGFR) (FIG. 2B, right panel). Supershift analysis with anti-
Stat3 antibody shows protein:DNA probe complex contains 
Stat3 (FIG. 2B, left panel, lane 8). By contrast, the plaid, 5 
pSrc and pErkl/2 (MAPKs) in NIH3T3/v-Src fibroblasts are 
not repressed by S3I-M2001(FIG.2C, lanes 7-12), indicating 
minimal effect on non-Stat3-related proteins. Furthermore, 
transient transfection and luciferase reporter studies showed 
S3I-M2001 inhibited v-Src-induced Stat3-dependent 10 
pLucTKS3 luciferase reporter, but not the v-Src-induced 
Stat3-independent pLucSRE luciferase reporter (17, 19), in a 
similar manner to the effect of the transient co-expression of 
the dominant-negative Stat3b (FIG. 3A) (17, 19). 
To confirm the disruption of Stat3:Stat3 dimerization, the 15 
previously reported dissociation-reassociation analysis (9, 
10, 20) was performed using pooled cell lysates of indepen-
dently-prepared lysates of activated Statl and Stat3 (details 
are provided in Supplementary Material, "RESULTS"). Statl 
or Stat3 DNA-binding activity was evident in their respective 20 
cell lysates (FIG. 3B, lanes 1 and 2) and present together in 
the pooled lysates (FIG. 3B, lane 3). Pooled lysate treated 
with S3I-M2001 showed a concentration-dependent diminu-
tion ofStat3:Stat3 DNA-binding activity (FIG. 3B, lanes 3-6) 
ahead of a diminishing Statl :Statl homodimer activity (FIG. 25 
3B, lanes 5-7), and the appearance of an intermediate band 
corresponding to Statl: Stat3 heterodimer activity, which was 
hitherto not present (FIG. 3B, lanes 5 and 6). The formation of 
the Statl :Stat3 band is due to the re-association between 
transient monomers of active Stat3 and Statl (9, 10). The 30 
disappearance of the activities for Stat3:Stat3 (FIG. 3B, lanes 
5-7) and Statl:Stat3 (FIG. 3B, lane 7) is due to dimer disrup-
tion, as previously observed forISS 610 (9, 10), and suggests 
a preferential disruption of Stat3:Stat3 over Statl:Statl 
homodimer (FIG. 2A, middle and right panels). By contrast, 35 
in vitro ELISA study of the pTyr-SH2 domain interaction 
between the unrelated Lek SH2-GST and its cognate phos-
phopeptide, biotinyl-e-Ac-EPQpYEEIEL-OH (22) (FIG. 3C, 
4th bar) showed minimal effect of S3I-M2001 at 30 or 100 
mM (FIG. 3C, compare bars 5 and 6 to bar 4). Thus, S3I- 40 
M2001 selectively disrupts Stat3: Stat3 dimers, thereby inhib-
iting Stat3 DNA-binding and transcriptional activities, while 
not affecting the Lck-SH2 domain function. On whether dis-
ruption of Stat3 dimerization inhibits nuclear translocation, 
immunofluorescence imaging/confocal microscopy for the 45 
nuclear localization of Stat3 in EGF-stimulated NIH3T3/ 
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(Stat3-YFP) plasmid (23) (NIH3T3/v-Src/Stat3-YFP) 
showed a stronger nuclear Stat3-YFP signal, consistent with 
constitutive Stat3 activation (FIGS. 4A, 4B and 4D, right 
panel, and 4E). Treatment with S3I-M2001 induced a time-
dependent decrease in the Stat3-YFP fluorescence; there is no 
change in signal at 1 h-treatment or less, while an increasing 
degree ofStat3 fluorescence loss becomes evident from 2-5 h, 
100-300 mM S3I-M200 I -treatment (FIG. 4A, time t=O to t=6 
h, left panels; arrows denote Stat3-YFP signal; FIG. 4B, 
second column from left compared to first, time t=O to t=2 h: 
FIG. 4D, right panel, time t=O to t=5 h)). Phase contrast 
microscopy showed cellular integrity was maintained (FIG. 
4A, time t=O to t=6 h, right panels; arrows identify cells 
remaining or originally positive for fluorescent signal). Pro-
tein degradation can result in fluorescence signal loss (29). 
Accordingly, the presence of MG132 proteasome inhibitor 
prevented the fluorescence loss (FIG. 4B, third colunm from 
left), while MG132 alone has no appreciable effect (FIG. 4B, 
fourth colunm from left), suggesting the Stat3 fluorescence 
decay may involve the ubiquitin-proteasome degradation 
pathway. In contrast, similar studies with the v-Src trans-
formed fibroblasts stably expressing the non-Stat3 related 
Green Fluorescent Protein (GFP) (NIH3T3v-Src/GFP) 
showed no evidence ofGFP signal change by S3I-M2001 or 
the proteasome inhibitor MG132 (FIG. 4C and FIG. 4D, left 
panel), thus excluding the possibility of non-specific fluores-
cence quenching or photo bleaching. Moreover, immunoblot-
ting of whole-cell lysates from NIH3T3/v-Src/Stat3-YFP 
fibroblasts showed reduced Stat3-YFP expression in S3I-
M2001-treated cells in 3 and 5 h, which was similarly par-
tially restored when cells were co-treated with MG 132 (FIG. 
SA, lanes 3 and 4 vs. lanes 5 and 6). That only a partial 
corresponding decrease in total Stat3 protein occurred (FIG. 
SA, middle panel, lanes 3 and 4) suggests a weak proteasome 
activity against total Stat3 protein. However, immunoblotting 
for ubiquitin of Stat3 immunoprecipitates (i.p.) from 
NIH3T3/v-Src fibroblasts showed a strong and time-depen-
dent increase in the level ofStat3 ubiquitination following the 
S3I-M2001 treatment, which occurred in parallel with partial 
and strong Stat3 protein reductions at 5 and 24 h, respectively 
(FIG. SB). These findings together raise the possibility there 
is an impairment of proteasome function (24, 25) at the early 
hours ( <5 h) of S3 I-M2001-treatment and suggests additional 
mechanisms contribute to the Stat3 fluorescence signal decay. 
Protein misfolding can lead to ubiquitin-proteasome deg-
radation, and aggregation into aggresomes (26-29). Aggre-
somes can lead to fluorescence signal loss (29) and impair-
ment of proteasome function (24, 25). Using laser scanning 
confocal microscopy, we observed that the specific loss of 
hEGFR mouse fibroblasts revealed a strong EGF-induced 
nuclear staining of Stat3 in the absence of S3I-M2001 (FIG. 
3D, 3rd panel from left), which was significantly attenuated 
upon treatment of cells with S3I-M2001 (FIG. 3D, 4th panel 
from left), suggesting inhibition ofStat3 activation blocks its 
nuclear localization. 
Intracellular Stat3 Processing. 
Malignant cell requirement for persistently-active Stat3 for 
the maintenance of the malignant phenotype is well-estab-
lished (17-19, 32, 33). How tumor cells regulate Stat3 to meet 
this requirement, however, is not defined. Moreover, while 
the inhibition of aberrant Stat3 activity results in malignant 
cells demise (9-13), the molecular details of Stat3 cellular 
processing and the fate of the protein within the context of 
such an inhibition have not been explored. Given S3I-
M2001 's specific anti-Stat3 properties, it was used to probe 
the intracellular processing and localization dynamics of 
aberrant Stat3. Fluorescent microscopy (Nikon Eclipse 
TE200) (FIG. 4A) and laser scanning confocal microscopy 
(FIG. 4B-4E) of the NIH3T3/v-Src fibroblasts stably-trans-
fected with the yellow fluorescent protein (YFP)-tagged Stat3 
50 Stat3-YFP signal in the NIH3T3/v-Src/Stat3-YFP that fol-
lows S3I-M2001-treatment (FIG. 4D, right colunm and 4E 
right column, time t=O to t=5 h) is accompanied by aggre-
gated bodies, possibly aggresomes of Stat3-YFP, within 5 h 
of S3I-M2001 treatment (FIG. 4E, right bottom panel; red 
55 arrow denotes bodies). By contrast, Cisplatin treatment pro-
duced no such effect (FIG. 4E middle column). Confirming 
these data, immunofluorescence imaging/confocal micros-
copy of Stat3 in NIH3T3/v-Src fibroblasts revealed that in 
contrast to the strong nuclear fluorescence of activated Stat3 
60 protein that occurred in "dot-like" structures resembling 
nuclear bodies (23) and the low cytoplasmic signal in the 
untreated cells (FIG. 6A, control), a strongly reduced Stat3 
fluorescence signal occurred that coincided with the appear-
ance of perinuclear aggregated bodies, possibly aggresomes 
65 in the S3I-M2001-treated cells within 3 hand later, with a 
stronger aggresome formation at 24-h treatment (FIG. 6A. 
S3I-M2001, time t=0.5 to t=24 h). Thus. S3I-M2001 pro-
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motes the disruption of activated Stat3 from "dot-like" 
nuclear bodies (23) into perinuclear aggresomes, which may 
explain the apparent low proteasome-mediated degradation 
16 
transformed fibroblasts (NIH3T3/v-Ras) lacking constitu-
tively-active Stat3 (FIG. 7B). Terminal nucleotidyl trans-
ferase-mediated nick end labeling (TUNEL) (FIG. 7C) and 
Annexin Vbindingwith Flow CytometricAnalyses (FIG. 7D, 
first and third pairs of bars) showed strong apoptosis in the 
NIH3T3/v-Src (3T3/v-Src) and MDA-MB-231 and MDA-
MB-435 cells harboring aberrant Stat3 and treated with S3I-
M2001, compared to minimal effect on normal NIH3T3, 
human breast epithelial MCF-1 OA, breast cancer MDA-MB-
453, and HUVEC, HAEC, and HL-60 cells that do not con-
tain aberrant Stat3. Validating that the S3I-M2001-induced 
apoptosis is due to interaction with its molecular target (Stat3 
SH2 domain), NIH3T3/v-Src fibroblasts (3T3/v-Src) tran-
siently-transfected with a plasmid encoding the Stat3 SH2 
domain (3T3/v-Src/ST3-SH2) and treated with S3I-M2001 
showed diminished apoptosis (FIG. 7D, compare middle two 
bars) compared to mock-transfected (3T3/v-Src/pcDNA3) 
(FIG. 7D, left two bars) or untransfected cells (FIG. 7D, right 
two bars). Moreover, Western blot analysis showed dimin-
in the early period of S3I-M2001-treatment. The Stat3 aggre-
some formation and signal loss are events specific to S3I- 5 
M2001, because they are not induced by Cisplatin (FIG. 6A, 
Cisplatin) and occur in the early hours ( <5 h) of treatment 
prior to change in cellular integrity (FIG. 4A and data not 
shown). The resting of NIH3T3/v-Src fibroblasts for 2 h 
following a 5-h S3I-M2001-treatment led to a partial recov- 10 
ery of Stat3 signal, while aggresomes remained (FIG. 6B, 
upper panel, compare right column vs. middle column, 5 
h-treated cells without recovery vs. control), suggesting 
effect of S3I-M2001 still persisted in the 2 h following drug 
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removal. By contrast, Stat3 immunofluorescence was com-
pletely recovered within 19-h of resting after 5-h treatment 
(FIG. 6B, lower panel, compare right column vs. middle 
column, 5 h-treated cells without recovery vs. control), either 
because S3I-M2001 's effect on Stat3 was reversible or that 
new Stat3 protein was synthesized. To investigate further and 20 ished Bcl-xL expression, a known Stat3-regulated and anti-
apoptotic gene (30 ), in the S3 I-M200 I -treated NIH3 T3/v-Src 
and MDA-MB-43 5 cells (FIG. 7E), suggesting repressed Bcl-
xL expression is part of the underlying mechanism for the 
S3I-M2001-induced apoptosis. 
Given Stat3 's importance in tumor growth and tumor pro-
gression (31 ), matrigel assay using Bio-Coat migration 
chambers showed significant S3I-M2001-induced inhibition 
of the migration of NIH3T3/v-Src (76%). MDA-MB-231 
(37%) and Pane-I (21 %), and the invasion ofNIH3T3/v-Src 
to demonstrate the perinuclear aggresome localization, 
immunofluorescence imaging/confocal microscopy was per-
formed on NIH3T3/v-Src fibroblasts harboring constitu-
tively-active Stat3 to assess the co localization with Hook2, an 
25 
adaptor protein important for the association of cargos with 
dynein for the transport on microtubules and for aggresome 
formation (26). As expected, a strong nuclear Stat3 staining is 
observed (FIG. 6C, left upper panel), which contrasts a 
Hook2 expression that appears ubiquitous (FIG. 6C, middle 
upper panel), without any evidence of colocalization. By 
contrast, S3I-M2001 induced the formation of perinuclear 
aggregated bodies of Stat3 (FIG. 6C, left bottom panel), 
which colocalized with Hook2 (FIG. 6C, middle and right 
bottom panels; red arrows denote aggregated bodies), sug-
gesting a possible association between the two proteins and 
implicating the Hook proteins in the Stat3 aggresome forma-
tion. 
30 (28%), MDA-MB-231 (48%)andPanc-I (38%)cellsharbor-
ing constitutively-active (FIG. SA: percent inhibition in 
parenthesis defined in "Methods" section). Furthermore, in 
xenograft models of human breast (MDA-MB-231 cells that 
harbors aberrant Stat3) tumor-bearing mice, the i.v. injection 
35 of S3I-M2001 at 5, 10, and 20 mg kg-I, but not vehicle (control) every 2 or 3 days for 26 days, strongly inhibited 
growth of tumors (FIG. SB). Animals remained viable at the 
highest (20 mg kg-I) dose applied. DNA-binding assay with 
EMSA analysis and SDS/AGE-Westem blotting of lysates 
from residual tumor tissues extracted from representative 
Together, our studies herein disclosed are the first on the 
localization dynamics and the molecular mechanisms for ter-
minating Stat3 function in response to a small-molecule 
inhibitor. Two possible mechanisms may account for the loss 
of aberrant Stat3 function: one involves protein ubiquitina-
tion and an early aggregation into perinuclear aggresomes 
(28), and a late-phase proteasome-mediated degradation 
event, potentially a "quality control" mechanism for Stat3 
(34), given its apparent unnatural state promoted by S3I-
M2001. The effects of early aggresome formation may be 
reversible, while the late-phase events are irreversible and 
lead to a long-term loss of Stat3 function, with biological 
consequences. The perinuclear aggresome formation also 
suggests a nuclear-to-perinuclear exit of disrupted "acti-
vated" Stat3 by as yet undetermined mechanisms. 
Suppression of Malignant Phenotype and Tumor Growth. 
Consistent with Stat3's importance in maintaining the 
malignant phenotype (17), WST-1 assay (FIG. 7A) and try-
pan blue exclusion/cell counting revealed S3I-M2001-in-
duced growth inhibition and a greater than 2-fold selective 
loss of viability of the human breast (MDA-MB-435 and 
MDA-MB-231) and Pancreatic (Pane-I) cancer cells, and the 
NIH3T3/v-Src fibroblasts, which all harbor constitutively-
active Stat3, with EC50 values in the range of 50-100 mM, 
compared to effects on normal NIH3T3 fibroblasts, and the 
human breast (MDA-MB-453) and Pancreatic (MiaPaca-1) 
cancer cells that lack aberrant Stat3 (EC50 values of 120-300 
mM) (FIG. 7 A). Furthermore, S3I-M200 I blocked growth in 
soft-agar of the NIH3T3/v-Src and the pancreatic cancer, 
Pane-I cells (FIG. 7B), and induced morphology changes in 
NIH3T3/v-Src, in contrast to no appreciable effects on v-Ras 
40 
control and treated mice showed abrogated Stat3 activity and 
pTyr levels in S3I-M2001-treated tumors (Tl and T2) (FIGS. 
SC and SD). These findings together demonstrate S3 I-M2001 
induces anti tumor cell effects and tumor regression in part by 
targeting the Stat3 SH2 domain and inhibiting Stat3-medi-
45 ated tumor processes (3, 6, 7, 17, 32, 38, 39). Moreover, 
S3I-M2001 compares favorably with other Stat3 SH2 
domain-targeting small-molecule inhibitors, including S3I-
201, which was obtained by computational modeling and 
virtual chemical library-screening (13), and represents a sig-
50 nificant improvement over its peptidomimetic predecessors 
(10). 
The present disclosure provides the first study of the cel-
lular processing and stability of aberrant Stat3 in malignant 
cells within the context ofinhibition by a chemical probe that 
55 has implications for the many human tumor cells, including 
the human breast and pancreatic cancer cells that harbor 
aberrant Stat3. The general applicability of the current study 
to other previously-identified Stat3 inhibitors, including the 
g-quartet oligonucleotides (35), peptide aptamers (36), plati-
num (IV) complexes (11, 12), and STA-21 (NSC 628869) 
60 (37), however, is unclear, as those other agents have different 
modes ofinhibitionofStat3 from S3I-M2001.Altogether, our 
studies establish the proof-of-concept for the antitumor 
effects of S3I-M2001 that correlates with disruption of con-
stitutively-active Stat3:Stat3 dimers, while using S3I-M2001 
65 as a chemical probe to investigate the molecule dynamics of 
termination of Stat3 function following inhibition. Accord-
ingly, the novel compound S3I-M2001 herein disclosed may 
US 8,609,639 B2 
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also be referred to as an anti-cancer agent, a cytotoxic agent 
and/or a chemotherapeutic agent. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 5 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 10 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
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2. A pharmaceutically acceptable composition containing 
the compound of claim 1. 
3. A pharmaceutically acceptable composition containing 
the compound of claim 1 in an effective amount for inhibiting 
Stat3 dimerization in a manmialian cell contacted with said 
composition. 
4. A method of treating a mammalian cell having a dys-
functional Stat3 protein, the method comprising contacting 
the cell with the compound of claim 1. 
5. A method of treating a mammalian cell, the method 
comprising contacting the cell with the composition of claim 
2. 
6. A method of treating a mammalian cell having a dys-
functional Stat3 protein, the method comprising contacting 
the cell with the composition of claim 2. 
7. A method of inhibiting a manmialian cell harboring 
constitutively active Stat3, the method comprising contacting 
the cell with an effective amount of the compound of claim 1. 
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That which is claimed: 
1. A compound, or a pharmaceutically acceptable salt 
thereof, having a structure represented by a formula: 
45 
50 
55 
60 
9. A method of treating human breast or pancreatic cancer 
cells having a constitutively active level of Stat3, the method 
comprising administering a sufficient amount of the com-
pound of claim 1 to contact said cancer cells. 
10. A method of treatment effective to inhibit growth of a 
human breast cancer tumor cell, the method comprising 
administering to the cell a sufficient amount of the compound 
of claim 1. 
11. A method of inhibiting migration of a malignant cell, 
the method comprising contacting the cell with the compound 
of claim 1. 
12. A method of treating a mammalian cancer having a 
dysfunctional level of Stat3, the method comprising contact-
ing the cancer with a therapeutically effective amount of the 
compound having a structure represented by a formula: 
13. A method of treating a mammalian cancer having a 
65 dysfunctional Stat3 protein, the method comprising contact-
ing the cancer with the compound having a structure repre-
sented by a formula: 
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14. A method of treating a human breast or pancreatic 
cancer cell, the method comprising contacting at least one cell 
of a human breast or pancreatic cancer with the composition 
of claim 2. 
15. A method of treating a mammalian cancer having a 
dysfunctional Stat3 protein, the method comprising contact-
ing the cell with the composition of claim 2. 
22 
16. A method of inhibiting a mammalian cancer having a 
constitutively active Stat3, the method comprising contacting 
the cancer with an effective amount of the compound of claim 
1. 
17. A method of treating a human breast cancer or pancre-
atic cancer, the method comprising contacting the cancer with 
an amount of the compound of claim 1 effective to inhibit 
Stat3 activity therein. 
18. A method of treating human breast or pancreatic cancer 
10 having a constitutively active level ofStat3, the method com-
prising administering a sufficient amount of the compound of 
claim 1 to contact said cancer. 
19. A method of patient treatment effective for inhibiting 
15 
growth of a human breast cancer tumor, the method compris-
ing administering to the patient a sufficient amount of the 
compound of claim 1 to contact the cancer tumor. 
20. A method of inhibiting migration of malignant cells 
from a mammalian cancer, the method comprising contacting 
20 
the cells with the compound of claim 1. 
21. A method of inhibiting growth of a human breast or 
pancreatic cancer tumor, the method comprising contacting at 
least one cell of a human breast or pancreatic cancer tumor 
with the compound of claim 1. 
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